Skip to main content
    E

    Edgewise Therapeutics Inc (EWTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $38.20
    +1.18 (+3.19%)

    Market Cap: $3.94B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(12/22)
    Avg Surprise
    +0.09%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$2.81
    Range$-0.64 - $11.45
    10 analysts
    EPS RevisionsNo revisions (7d)
    1
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$1.13+147.8%
    60d ago$1.18+138.2%
    30d ago$2.810.0%
    7d ago$2.810.0%
    Current$2.81
    Revenue Consensus
    $129M
    Range$0 - $1.6B
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.47
    Range$-4.27 - $8.43
    10 analysts
    Revenue Consensus
    $10M
    Range$-129166670 - $1.5B
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.47---
    Sep 26EST
    		-$2.81---
    Jun 26
    Reported Aug 6
    		$-0.53$-0.48-10.42%Miss-55.9%
    Mar 26
    Reported May 7
    		$-0.46$-0.48+4.17%Beat-7.0%
    Dec 25
    Reported Feb 26
    		$-0.47$-0.43-9.30%Miss-11.9%
    Sep 25
    Reported Nov 6
    		$-0.39$-0.40+2.50%Beat-8.3%
    Jun 25
    Reported Aug 7
    		$-0.34$-0.42+19.05%Beat+0.0%
    Mar 25
    Reported May 8
    		$-0.43$-0.42-2.38%Miss-30.3%
    Dec 24
    Reported Mar 3
    		$-0.42$-0.42+0.52%Beat+10.6%
    Sep 24
    Reported Nov 7
    		$-0.36$-0.37+2.70%Beat+12.2%
    Jun 24
    Reported Aug 8
    		$-0.34$-0.34+0.00%Beat+0.0%
    Mar 24
    Reported May 9
    		$-0.33$-0.41+19.51%Beat+8.3%
    Dec 23
    Reported Feb 22
    		$-0.47$-0.43-9.30%Miss-51.6%
    Sep 23
    Reported Nov 9
    		$-0.41$-0.40-2.50%Miss-20.6%
    Jun 23
    Reported Aug 10
    		$-0.34$-0.40+15.00%Beat-6.3%
    Mar 23
    Reported May 11
    		$-0.36$-0.35-2.86%Miss-20.0%
    Dec 22
    Reported Feb 23
    		$-0.31$-0.33+6.06%Beat-19.2%
    Sep 22
    Reported Nov 3
    		$-0.34$-0.36+5.56%Beat-30.8%
    Jun 22
    Reported Aug 4
    		$-0.32$-0.32+0.00%Beat-52.4%
    Mar 22
    Reported May 11
    		$-0.30$-0.28-7.14%Miss-114.3%
    Dec 21
    Reported Feb 24
    		$-0.26$-0.25-4.00%Miss-
    Sep 21
    Reported Nov 10
    		$-0.26$-0.24-8.33%Miss-
    Jun 21
    Reported Aug 9
    		$-0.21$-0.17-23.53%Miss-
    Mar 21
    Reported May 13
    		$-0.14$-0.15+6.67%Beat-
    Dec 20
    Reported Mar 26
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-20.65EV/EBITDAN/A
    Price/FCF-25.89xFCF Yield-3.86%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-38.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio16.24xQuick Ratio16.24x
    Trading Statistics
    Beta0.35Avg Volume1.71M
    52-Week High$48.5152-Week Low$14.68

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$38.95
    SMA 20$40.28
    SMA 50$42.44
    SMA 200$35.48
    EMA 10$38.69
    EMA 20$39.90
    EMA 50$41.00
    EMA 200$35.43

    MACD

    Line: -1.40Signal: -1.11Hist: -0.29

    ADX

    ADX: 16.9+DI: 17.6-DI: 30.7

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down96.0
    PSAR$40.18

    Bollinger Bands

    Upper Band$44.98
    Lower Band$35.58
    %B Position2333%(Upper)
    Band Width0.28

    RSI (14-Day)

    Neutral
    40.5

    Momentum Oscillators

    Stoch %K21.4
    Stoch %D16.3
    Williams %R-60.4
    ROC (10d)-5.6%
    Momentum-2.28
    CCI (20d)-93.7
    MFI (14d)32.9

    Volatility Measures

    ATR (14d)$1.98(5.2%)
    StdDev (20d)2.35
    Hist Vol45.3%(High)

    Volume Flow

    VWAP$37.99
    OBV14.1M
    AD Line13.0M
    CMF (20d)-0.225

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio1.0x
    VWMA (20d)$40.44

    Pivot Points

    R3$40.41
    R2$39.17
    R1$38.10
    Pivot Point$36.86
    S1$35.79
    S2$34.55
    S3$33.48

    Advanced Oscillators

    TSI-22.09
    Ultimate Osc42.0
    KST-104.49

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$2.12M$0$0$0$2.25M$0
    Cost of Revenue$0$0N/A$0$0$0$1.06M$0$0$0$533,000$0
    Gross Profit$0$0N/A$0$0$0$1.06M$0$0$0$1.72M$0
    Operating Expenses$61.94M$54.12M$55.98M$46.86M$42.61M$45.96M$45.54M$40.43M$38.11M$34.75M$33.86M$29.45M
    R&D$47.55M$42.65M$43.59M$37.48M$33.56M$36.76M$36.37M$32.22M$30.68M$27.69M$27.68M$23.79M
    SG&A$14.39M$11.46M$12.38M$9.38M$9.05M$9.20M$9.17M$8.21M$7.43M$7.06M$6.18M$5.67M
    Operating Income$-61,943,000$-54,115,000$-55,979,000$-46,858,000$-42,610,000$-45,959,000$-45,540,000$-40,432,000$-38,107,000$-34,753,000$-33,862,000$-29,452,000
    Interest Income$4.62M$5.10M$5.76M$6.19M$6.50M$5.16M$5.88M$6.30M$6.61M$6.23M$3.72M$3.74M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-57,327,000$-49,013,000$-50,216,000$-40,666,000$-36,115,000$-40,798,000$-39,662,000$-34,129,000$-31,497,000$-28,525,000$-30,143,000$-25,713,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-57,327,000$-49,013,000$-50,216,000$-40,666,000$-36,115,000$-40,798,000$-39,662,000$-34,129,000$-31,497,000$-28,525,000$-30,143,000$-25,713,000
    EBITDA$-62,155,000$-54,538,000$-56,887,000$-48,344,000$-44,246,000$-47,328,000$-47,513,000$-43,070,000$-41,126,000$-37,378,000$-35,501,000$-31,330,000
    EBIT$-61,943,000$-54,115,000$-55,979,000$-46,858,000$-42,610,000$-45,959,000$-45,540,000$-40,432,000$-38,107,000$-34,753,000$-33,862,000$-29,452,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EWTX

    News

    William Blair initiates Edgewise Therapeutics stock with outperform rating By Investing.com

    William Blair has initiated coverage on Edgewise Therapeutics (NASDAQ: EWTX) with an outperform rating, setting a DCF-adjusted valuation of $53 per share, while the stock currently trades at $38.20. The company...

    Investing.com Australia•10/16/26•Bullish

    H.C. Wainwright reiterates Edgewise Therapeutics stock rating at buy By Investing.com

    H.C. Wainwright has reiterated its Buy rating and $57.00 price target for Edgewise Therapeutics (NASDAQ:EWTX). This reaffirmation comes after the company presented promising Phase 1 data for its investigational drug...

    Investing.com Canada•10/14/26•Bullish

    H.C. Wainwright reiterates Edgewise Therapeutics stock rating at buy By Investing.com

    H.C. Wainwright has reaffirmed its Buy rating and $57.00 price target for Edgewise Therapeutics (NASDAQ: EWTX) following the company's presentation of positive Phase 1 data for its investigational drug EDG-15400....

    Investing.com Nigeria•10/14/26•Bullish

    Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $51

    Piper Sandler has reaffirmed its Buy rating for Edgewise Therapeutics (EWTX.US) and maintained its price target at $51. This indicates a continued positive outlook from the analyst firm regarding the company's stock...

    Moomoo•10/13/26•Bullish

    (EWTX) Movement as an Input in Quant Signal Sets

    This article analyzes Edgewise Therapeutics Inc. (NASDAQ: EWTX) using AI-generated quantitative signals. It highlights weak near and mid-term sentiment but a strong long-term outlook...

    Stock Traders Daily•10/11/26•Somewhat-Bearish

    EWTX Valuation and Fair Value

    P/E
    -20.6x
    P/FCF
    -25.9x
    P/B
    9.2x
    See GNG's fair value

    EWTX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -38.0%
    FCF yield
    -3.9%

    EWTX Competitors

    CompanyTicker
    Indivior PLC Ordinary SharesINDV
    Catalyst Pharmaceuticals IncCPRX
    Adaptive Biotechnologies CorpADPT
    Tango Therapeutics IncTNGX
    Premier IncPINC
    Envista Holdings CorpNVST
    Regencell Bioscience Holdings LtdRGC
    Telix Pharmaceuticals LimitedTLX

    Sector: Healthcare

    EWTX Analyst Ratings

    Consensus
    Buy
    Analysts
    13
    Strong Buy
    3
    Buy
    8
    Hold
    2
    Sell
    0
    Strong Sell
    0

    EWTX Bull Case vs Bear Case

    Bull case

    • 84.6% of EWTX's analyst ratings are Buy or Strong Buy.

    EWTX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    0.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $2.81
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 4 down

    Frequently Asked Questions About EWTX

    Does EWTX pay dividends?

    Edgewise Therapeutics Inc (EWTX) does not currently pay a regular dividend.

    What is EWTX's market cap?

    Edgewise Therapeutics Inc (EWTX) has a market capitalization of $3.94B with a current stock price of $38.20.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In